Form 13-F position report

ULTRAGENYX PHARMACEUTICAL INC

Reported by Columbia Wanger Asset Management LLC

RARE CUSIP 90400D108 Manager CIK 0000908733

Reported 1,364,434 shares, up 126,609 (10.2%) from the prior quarter.

Reported value 1.0%; share count 10.2% vs. the prior quarter.

Added
% of reported 13F value 1.21% This manager · Q2 2017
Shares 1,364,434 Quarter-end amount reported
Reported value $84,745,000 Fair value at quarter end
Consecutive quarters held 14 Through Q2 2017

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2014-03-31 81868000
2014-06-30 77393000
2014-09-30 101375000
2014-12-31 58386000
2015-03-31 139374000
2015-06-30 238996000
2015-09-30 120639000
2015-12-31 124695000
2016-03-31 60850000
2016-06-30 42229000
2016-09-30 89191000
2016-12-31 82658000
2017-03-31 83900000
2017-06-30 84745000
2017-09-30 85021000
2017-12-31 67000000

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for ULTRAGENYX PHARMACEUTICAL INC held by Columbia Wanger Asset Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2017 Reduced 1,444,584 -151,750 (-9.5%) 1.0% $67,000,000 2018-02-13
Q3 2017 Added 1,596,334 +231,900 (17.0%) 1.26% $85,021,000 2017-11-13
Q2 2017 Added 1,364,434 +126,609 (10.2%) 1.21% $84,745,000 2017-08-11
Q1 2017 Added 1,237,825 +62,209 (5.3%) 1.18% $83,900,000 2017-05-12
Q4 2016 Reduced 1,175,616 -81,655 (-6.5%) 1.16% $82,658,000 2017-02-10
Q3 2016 Added 1,257,271 +393,879 (45.6%) 1.17% $89,191,000 2016-11-10
Q2 2016 Reduced 863,392 -97,753 (-10.2%) 0.49% $42,229,000 2016-08-12
Q1 2016 Reduced 961,145 -150,421 (-13.5%) 0.66% $60,850,000 2016-05-12
Q4 2015 Reduced 1,111,566 -141,048 (-11.3%) 1.25% $124,695,000 2016-02-08
Q3 2015 Reduced 1,252,614 -1,081,559 (-46.3%) 0.96% $120,639,000 2015-11-10
Q2 2015 Added 2,334,173 +89,463 (4.0%) 1.54% $238,996,000 2015-08-13
Q1 2015 Added 2,244,710 +914,143 (68.7%) 0.76% $139,374,000 2015-05-01
Q4 2014 Reduced 1,330,567 -460,515 (-25.7%) 0.29% $58,386,000 2015-02-06
Q3 2014 Reduced 1,791,082 -2,100 (-0.1%) 0.47% $101,375,000 2014-11-12
Q2 2014 Reduced 1,793,182 -2,300 (-0.1%) 0.31% $77,393,000 2014-08-12
Q1 2014 New 1,795,482 +1,795,482 (0.0%) 0.32% $81,868,000 2014-05-12

Who else reported the position

164 managers reported ULTRAGENYX PHARMACEUTICAL INC for Q2 2017.

Managers reporting ULTRAGENYX PHARMACEUTICAL INC in Q2 2017.
Manager Activity Shares Change % of reported 13F Reported value Tenure
WELLINGTON MANAGEMENT GROUP LLP Added 5,247,141 +666,197 0.08% $325,899,000 14 qtrs
Capital Research Global Investors Added 5,183,330 +71,811 0.1% $321,937,000 14 qtrs
FMR LLC Reduced 3,804,225 -2,306,402 0.03% $236,280,000 14 qtrs
BlackRock Inc Added 3,497,591 +330,911 0.01% $217,237,000 14 qtrs
VANGUARD GROUP INC Added 3,130,273 +135,335 < 0.01% $194,421,000 14 qtrs
Capital International Investors Added 2,374,985 +198,252 0.2% $147,510,000 4 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 1,761,589 +90,765 0.02% $109,412,000 14 qtrs
STATE STREET CORPORATION Added 1,536,285 +270,729 < 0.01% $95,417,000 14 qtrs
Columbia Wanger Asset Management LLC This report Added 1,364,434 +126,609 1.21% $84,745,000 14 qtrs
ALLIANCEBERNSTEIN L P Added 689,206 +114,897 0.03% $42,807,000 14 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2017
Filed
August 11, 2017
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,280,094
Shared
0
None
84,340

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.